Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRPK1 | Q96SB4 | 9/20 | 0.66 |
| ▸ | SRPK2 | P78362 | 7/20 | 0.66 |
| ▸ | ALK | Q9UM73 | 17/20 | 0.66 |
| ▸ | EML4 | Q9HC35 | 6/20 | 0.64 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.62 |
| ▸ | CLK1 | P49759 | 1/20 | 0.62 |
| ▸ | CLK2 | P49760 | 1/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.62 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.62 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.62 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528746 | 1.00 | SRPK1 (0.66) | SRPK1SRPK2ALKEML4DYRK3 | |
| SCHEMBL30009797 | 0.89 | ALK (0.54) | SRPK1SRPK2ALKEML4DYRK3 | |
| SCHEMBL30713726 | 0.89 | ALK (0.54) | SRPK1SRPK2ALKEML4DYRK3 | |
| SCHEMBL20366576 | 0.86 | ALK (0.70) | SRPK1SRPK2ALKEML4 | |
| SCHEMBL31507375 | 0.86 | ALK (0.70) | SRPK1SRPK2ALKEML4 | |
| SCHEMBL20494830 | 0.86 | SRPK1 (0.74) | SRPK1SRPK2ALKEML4DYRK3 | |
| SCHEMBL30715047 | 0.86 | SRPK1 (0.74) | SRPK1SRPK2ALKEML4DYRK3 | |
| SCHEMBL29940400 | 0.85 | ALK (0.54) | SRPK1SRPK2ALKEML4DYRK3 | |
| SCHEMBL897726 | 0.84 | ALK (0.71) | SRPK1SRPK2ALK | |
| SCHEMBL897781 | 0.84 | ALK (0.71) | SRPK1SRPK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | claimed |
| EP-2975024-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-03-28 | — | — | EP | claimed |
| US-12390532-B2 | ALK protein regulator and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2025-08-19 | — | — | US | disclosed |
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2025-02-27 | — | — | US | disclosed |
| US-12233128-B2 | Degraders that target ALK and therapeutic uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | SHANGHAITECH UNIVERSITY (CN) | 2025-02-18 | — | — | US | disclosed |
| US-11858897-B2 | Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220409731-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-29 | — | — | US | disclosed |
| EP-2975024-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2975024-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | SRPK1 3208/4885SRPK2 3230/4885ALK 1/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | SRPK1 3208/4885SRPK2 3230/4885ALK 1/4885 |
| US-12390532-B2 | ALK protein regulator and anti-tumor application thereof | ALK, MYC, ALKBH3 | SRPK1 1447/4885SRPK2 1784/4885ALK 1/4885 |
| US-12233128-B2 | Degraders that target ALK and therapeutic uses thereof | ALK, BCR, IDE | SRPK1 2794/4885SRPK2 2445/4885ALK 1/4885 |
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | SRPK1 1218/4885SRPK2 1671/4885ALK 2330/4885 |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | UFM1, SUMO1, SUMO2 | SRPK1 1217/4885SRPK2 1641/4885ALK 2497/4885 |
| US-11858897-B2 | Substituted 6,11-dihydro-5H-benzo[b]carbazoles as inhibitors of ALK and SRPK | SRPK3, SRPK1, SRPK2 | SRPK1 2/4885SRPK2 3/4885ALK 4/4885 |
| US-20220409731-A1 | DEGRADERS THAT TARGET ALK AND THERAPEUTIC USES THEREOF | ALK, BCR, FAP | SRPK1 2864/4885SRPK2 2432/4885ALK 1/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | SRPK1 3208/4885SRPK2 3230/4885ALK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.